A study found prolonged-release melatonin (PedPRM) to be safe and effective for autistic children who have insomnia that does not respond to behavioural intervention, Neurology Advisor reports. The results of the a randomised, double-blind, placebo-controlled trial are published in the Journal of the American Academy of Child & Adolescent Psychiatry. The study was led by Professor Paul Gringras of the Children’s Sleep Medicine Department, Evelina London Children Hospital. The PedPRM is administrated in the form of a mini-tablet, which makes it easier to take for autistic children who have difficulties swallowing.
Date added: 12 October 2017